CLSN
$2.21
Celsion
$.03
1.38%
CLSN
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  ($0.35)
Revenue:  $0.13 Mil
Wednesday
Feb 27
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CLSN reports earnings?
Beat
Meet
Miss

Where is CLSN's stock price going from here?
Up
Flat
Down
Stock chart of CLSN
Analysts
Summary of analysts' recommendations for CLSN
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.
Peers
BioMarin PharmaceuticalVertex PharmaceuticalsRegeneron PharmaceuticalsCelgeneInterCeptMylanUltragenyx PharmaceuticalEndo International plcJohnson & JohnsonPerrigo